These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 16773180)
41. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458 [TBL] [Abstract][Full Text] [Related]
42. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells. Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814 [TBL] [Abstract][Full Text] [Related]
43. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633 [TBL] [Abstract][Full Text] [Related]
44. [Cancer-associated gene abnormalities and chemosensitivity]. Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804 [TBL] [Abstract][Full Text] [Related]
45. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635 [TBL] [Abstract][Full Text] [Related]
46. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Torng PL; Lee YC; Huang CY; Ye JH; Lin YS; Chu YW; Huang SC; Cohen P; Wu CW; Lin CT Oncogene; 2008 Apr; 27(15):2137-47. PubMed ID: 17952116 [TBL] [Abstract][Full Text] [Related]
47. Screening for genes associated with ovarian cancer prognosis. Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465 [TBL] [Abstract][Full Text] [Related]
48. Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation. Wang Y; Zhang Z; Lu Y; Yao R; Jia D; Wen W; LaRegina M; Crist K; Lubet R; You M Mol Cancer Res; 2008 Jan; 6(1):99-109. PubMed ID: 18234966 [TBL] [Abstract][Full Text] [Related]
49. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Leoutsakou T; Talieri M; Scorilas A Biochem Biophys Res Commun; 2006 Jun; 344(2):667-74. PubMed ID: 16631123 [TBL] [Abstract][Full Text] [Related]
50. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Richardson A; Kaye SB Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989 [TBL] [Abstract][Full Text] [Related]
51. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Zorn KK; Jazaeri AA; Awtrey CS; Gardner GJ; Mok SC; Boyd J; Birrer MJ Clin Cancer Res; 2003 Oct; 9(13):4811-8. PubMed ID: 14581352 [TBL] [Abstract][Full Text] [Related]
53. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Taxman DJ; MacKeigan JP; Clements C; Bergstralh DT; Ting JP Cancer Res; 2003 Aug; 63(16):5095-104. PubMed ID: 12941840 [TBL] [Abstract][Full Text] [Related]
54. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968 [TBL] [Abstract][Full Text] [Related]
55. GBP1 overexpression is associated with a paclitaxel resistance phenotype. Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104 [TBL] [Abstract][Full Text] [Related]
56. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604 [TBL] [Abstract][Full Text] [Related]
57. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Cappelletti V; Gariboldi M; De Cecco L; Toffanin S; Reid JF; Lusa L; Bajetta E; Celio L; Greco M; Fabbri A; Pierotti MA; Daidone MG Endocr Relat Cancer; 2008 Jun; 15(2):439-49. PubMed ID: 18508997 [TBL] [Abstract][Full Text] [Related]
58. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661 [TBL] [Abstract][Full Text] [Related]
59. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Yim EK; Tong SY; Ho EM; Bae JH; Um SJ; Park JS Oncol Rep; 2009 Feb; 21(2):549-57. PubMed ID: 19148534 [TBL] [Abstract][Full Text] [Related]
60. Identification of gene expression signatures for molecular classification in human leukemia cells. Song JH; Kim HJ; Lee CH; Kim SJ; Hwang SY; Kim TS Int J Oncol; 2006 Jul; 29(1):57-64. PubMed ID: 16773185 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]